February 20, 2026
China's biotech influence grows, FDA's recent actions spark debate, and the XBI's future is analyzed alongside key clinical and company news.
February 6, 2026
Biotech Hangout covers a hot 2026 IPO market, key policy shifts, the obesity drug battle between Lilly & Novo, and major pipeline updates.
January 30, 2026
Bio CEO John Crowley on the US-China biotech race, FDA reform, and policy hurdles like MFN. Plus, market takes on the IRA, gene therapy, and more.
January 23, 2026
Biotech Hangout covers 2026 market optimism, M&A trends, the reopening IPO window, policy wins, FDA guidance, and key deals in women's health.
January 16, 2026
Biotech's 2026 outlook is a healthy '7/10' post-JPM. Optimism is driven by investor interest, strong financing, and key data, despite FDA scrutiny.
January 9, 2026
Biotech starts 2026 with a bullish outlook, fueled by M&A rumors (Revolution Medicine), a successful IPO (Actis), and promising clinical data.
December 19, 2025
Biotech Hangout's 2025 recap: A market rebound faces year-end fatigue. Experts discuss the 2026 IPO outlook, FDA policy risks, and M&A.
December 12, 2025
Biotech sees a policy shift with the NDAA's Biosecure Act, yet market sentiment rises on strong financing & breakthrough data from ASH and Esmo.
December 5, 2025
Biotech insiders are bullish on 2026, anticipating a strong IPO market but cautioning against FDA leadership chaos and regulatory uncertainty.
November 21, 2025
Biotech sees a hot M&A streak with record deals for early-stage assets, while policy shifts in DC and drug pricing wars add market complexity.
November 7, 2025
Biotech Hangout covers FDA leadership chaos and regulatory volatility, impacting Unicure, Sarepta, and investor confidence across the industry.
